Damage-associated molecular patterns (DAMPs) are released in response to cell death and stress, and are potent triggers of sterile inflammation. Recent evidence suggests that DAMPs may also have a key role in the development of cancer, as well as in the host response to cytotoxic anti-tumor therapy. As such, DAMPs may exert protective functions by alerting the immune system to the presence of dying tumor cells, thereby triggering immunogenic tumor cell death. On the other hand, cell death and release of DAMPs may also trigger chronic inflammation and, thereby promote the development or progression of tumors. Here, we will review the contribution of candidate DAMPs and their receptors, and discuss the evidence for DAMPs as tumor-promoting and anti-tumor effectors, as well as unsolved questions such as DAMP release from non-tumor cells as well as the existence of tumorspecific DAMPs.
INTRODUCTION
Cancers have been described as 'wounds that do not heal', 1 suggesting that multiple components of the wound-healing process also contribute to carcinogenesis. This notion is supported by a landmark study by Dolberg et al., 2 demonstrating that wounding strongly promotes the development of tumors following injection of Rous Sarcoma virus. Likewise, clinical evidence suggest more common recurrence of tumors in resection margins, that is, sites in which wound healing occurs, often with poorer differentiation and dismal prognosis. 3 Together, these studies suggest that injury and subsequent wound healing promote the development of cancer. Injured or stressed cells release a plethora of mediators, termed damage-associated molecular patterns (DAMPs), which potently trigger sterile inflammation. DAMPs represent a large range of chemically unrelated mediators such as High Mobility Group Box 1 (HMGB1), S100 proteins, hyaluronan, heat-shock proteins, adenosine triphosphate (ATP) and calreticulin that are retained inside the cell in the healthy state and only released following stress or cell death, thus allowing the host to sense and react to damage via specific DAMP receptors. Although DAMPs were initially considered to be exclusively released from necrotic cells, recent evidence suggest that specific forms of programmed cell death such as necroptosis and immunogenic cell death (ICD) following anti-cancer therapies [4] [5] [6] [7] can also trigger DAMP emission into the extracellular space. DAMP-mediated sterile inflammation is an important component of a wide range of diseases, including atherosclerosis, myocardial infarction, autoimmune diseases and cancer. 8 As there are several excellent reviews on DAMPs and their receptors, 4,8-10 we will selectively focus on their involvement in cancer in this review.
There are multiple parallels between innate immune responses to pathogens and cell death, such as the use of specific pattern-recognition receptors (PRRs), and the occurrence of neutrophils and inflammation at sites of infection or injury. Hence, these pathways can be classified as a common danger-response system that can be activated by either pathogen-associated molecular patterns or DAMPs, in order to combat danger and restore tissue homeostasis. DAMPs could not only warn the body about the presence of tissue injury in sterile conditions, but also in the setting of infection, for example, when pathogens induce cell death, and thereby trigger more profound immune responses. In analogy, death of premalignant or malignant cells might allow a more potent anti-tumor response or immunosurveillance. As such, there is accumulating evidence that anti-tumor therapies, including radiation therapy and select chemotherapeutic agents, not only trigger direct cytotoxic effects, but also contribute to subsequent priming of the immune system and immune-mediated anti-tumor responses. 7, 11, 12 On the other hand, inflammation is a double-edged sword that may not only trigger anti-tumor immune responses, but also promote carcinogenesis in many settings ( Table 1 ). Failure of DAMPs to elicit an effective antitumor response might turn DAMP-induced inflammation into a tumor-promoting mechanism 13,14 -similar to wound healing, which often becomes maladaptive when injury is chronic. 15 Here, we will discuss the possible roles of DAMPs in cancer, focusing not only on DAMPs as mediators of immunogenic tumor death, but also the possible roles of DAMPs as triggers of tumor-promoting inflammation, as well as changes in the tumor microenvironment. (Table 1) . DAMPs are released in response to different modes of cell death (apoptosis, necroptosis, necrosis) and their release is regulated by different mechanisms and occurs at different stages of cell death. Although it is believed that necrotic and necroptotic cell death are more inflammatory than apoptotic cell death, this concept needs to be more rigorously tested in context-specific settings. 16 As tumors grow, metabolic demands increase and cancer cells are inevitably exposed to metabolic, hypoxic, genetic and/or mechanical stress, leading to the induction of cell death, often visible as a necrotic tumor core. 17 Whether this type of cell death is largely necrotic, necroptotic, apoptotic or a mix of all these remains to be determined and is likely to be tumor-specific. Although there is evidence for DAMP release in the setting of spontaneous tumor cell death, for example, a strong increase of extracellular ATP and adenosine within tumors, 18, 19 the release of DAMPs is much better documented during anti-tumor therapy. [20] [21] [22] As such, therapeutic interventions such as chemo-and radiotherapy, and oncolytic viruses trigger profound DAMP release. 12, 23, 24 The predominant form of cell death by these therapeutic interventions appears to be apoptosis, 11, 12 but other forms of cell death also participate, 17, 25, 26 and the mode of cell death likely determines the spectrum and activity of released DAMPs. Finally, cancer cells may also release DAMPs through stress pathways that either precede or are not directly related to cell death. Treatment with anthracyclins or photodynamic therapy result in the early translocation of calreticulin (CRT) to the cell surface before affected cells exhibit biochemical signs of apoptosis. 5, 6 CRT is not a classical DAMP, as it is not secreted, and appears to be selectively operating as an 'eat me' signal to stimulate the engulfment of apoptotic cells by dendritic cells (DCs). 5, 27 Mechanistically, surface exposure of CRT is triggered by endoplasmic reticulum (ER) stress. 6 Another example is the release of ATP, which is mediated by active secretion from dying cancer cells preceding the post mortem release of HMGB1. 28 ATP release in this setting is triggered by activation of caspases, which contribute to the redistribution of ATP from lysosomes to autolysosomes, as well as the opening of pannexin 1 channels. 28 Extracellular ATP can be converted into adenosine, which acts through distinct receptors that often result in immunosuppressive effects opposing the immunostimulatory effects of ATP. There is accumulating evidence on adenosine accumulation in the tumor environment, thus creating an immunosuppressed 'tumor-friendly' niche. 19 Increased levels of extracellular adenosine are the result of increased expression of ectonucleotidases CD39 and CD73. 29 In addition, several tumors show altered purine metabolism, which facilitates the production of adenosine or reduces its degradation. 19 Moreover, some DAMPs such as HMGB1 can not only passively leak from dying cells, but also be actively secreted via mechanisms that require post-translational modifications, such as acetylation and translocation from the nucleus to the cytosol. 30 In hypoxic hepatocellular carcinoma, HMGB1 is almost exclusively located in the cytoplasm 31 and hypoxia is sufficient to trigger HMGB1 release in carcinoma cell lines, 31 suggesting that cell death-independent HMGB1 secretion is also operative in cancer. Recent publications show lower nuclear HMGB1 staining in a large percentage of human tumor samples, which might-rather than indicating lower HMGB1 expression by the tumor-also indicate increased HMGB1 secretion. 32 Indeed, human malignant mesothelioma biopsies have been shown to display a variable degree of HMGB1 cytoplasmic staining, absent in normal pleura, that correlated with tumor stage. 33 Many members of S100 protein family, which serve as intracellular Ca 2+ sensors under physiologic conditions but also as DAMPs under pathologic conditions, exhibit cancer-type-specific patterns of dysregulated expression, with most evidence pointing toward overexpression and cancer promotion. 22 S100 proteins lack a leader sequence, precluding secretion via the classical Golgi pathway. Although S100A8/A9 can be actively secreted in a microtubule-and proteinase kinase C-dependent manner, both S100A8/A9 and S100B can also be passively released by injured tissues. 34 However, the precise mechanisms, by which they are released in cancer, are currently unknown. Interleukin (IL)-1a is released by many cell types upon activation or following necrosis, and IL-1 signaling has been implicated in the response to necrotic cell death. 35 The precursor form of IL-1a is upregulated and subsequently released from dying cells following hypoxia. 36 IL-1a released by necrotic hepatocytes contributes to compensatory proliferation and carcinogenesis. 36 IL-1a exists not only as a soluble form, whose maturation and secretion is inflammasome and caspase-1 dependent, 37 but also as a cell-surface protein that is able to activate IL-1 receptor-like 1 on target cells such as T cells and endothelial cells and potentiates the induction of other cytokines. 38 Although the secreted form of IL-1a is highly pro-inflammatory in the tumor microenvironment and involved in tumor growth and invasiveness, its membrane form favors anti-tumor immunity, and leads to reduced tumor growth and invasiveness. 38 IL-33 is another cytokine released by necrotic cells and by a variety of tissue types under stress conditions. 39 Endogenous IL-33 expression is increased in tumor tissue and contributes to cancer progression. [40] [41] [42] IL-33 upregulation in tumor also correlates with increased expression of targetreceptor complex IL-1 receptor-like 1 in stromal cells, 41, 42 reflecting a paracrine effect of IL-33 as a result of the crosstalk between tumor cells and surrounding stroma. In addition to DAMPs secreted within tumors, it is also conceivable that DAMP secretion from cells in the tumor microenvironment can modulate tumor biology and development. However, this area requires further investigation.
Although there is ample evidence for DAMP release in multiple settings, much of the current data is based on cell lines and animal models. Further studies are required to understand DAMP release in human cancer patients, to what degree therapeutic inventions alter DAMP release and whether DAMP levels correlate with therapeutic prognosis or clinical outcome. In systemic therapies, it is likely that DAMPs are not only released from tumors but that a large proportion of DAMPs are derived from other cell types that are typically affected by chemotherapy or irradiation such as intestinal epithelia. Hence, DAMPs from these cells rather than tumor-derived DAMPs might also affect inflammation and immune responses.
CONTRIBUTION OF DAMPS TO TUMOR PROMOTION VIA INFLAMMATION OR IMMUNOSUPPRESSION
Although acute inflammation is often beneficial for the host and an essential component of pathogen defense and tissue repair, failure to eliminate the causative agent leads to chronic unresolved inflammation that promotes maladaptive wound healing and increased risk to develop cancer, as demonstrated in animal models 13, 14, 43 and humans. 13 Mechanistically, inflammation predisposes to malignant transformation via multiple mechanisms, including (i) genetic damage caused by inflammation-associated reactive oxygen species and reactive nitrogen intermediates, (ii) promotion of proliferation via cytokineinduced growth factors and (iii) resistance to cell death via activation of anti-apoptotic cell death pathways such as nuclear factor-κB (NF-κB). Accordingly, the most prevalent conditions predisposing to cancer all have significant inflammatory components, such as chronic infections (that is, H. pylori, HBV, HCV, HPV), exposure to inhalative pathogens (including cigarette smoke, asbestos, silica) as well as obesity. 13, 44, 45 In addition to inflammatory conditions that promote the development of tumors, inflammation is also an essential component of established tumors. Of note, inflammation is not merely an epiphenomenon but an essential driver of tumor growth, whose significance for the progression of malignant disease is highlighted by its inclusion as a novel 'hallmark of cancer'. 46 The role of tumor-associated inflammation is highly context-, stage-and tumor-specific. Although inflammation in early stages may contribute to antitumor responses, immune cell exhaustion and loss of neoantigens after initial successful immunoediting may switch inflammation into a tumor-promoting response once anti-tumor immunity starts failing. 47, 48 DAMPs including HMGB1, S100 and heat-shock proteins, act via potent PRRs that are also employed by pathogen-associated molecular patterns such as Toll-like receptors (TLRs), formyl peptide receptor (FPR), C-type lectins and the receptor for advanced glycation endproducts (RAGE). These receptors activate a shared set of inflammatory pathways, including NF-κB, p38, ERK, inflammasome assembly, and IL-1β and IL-18 release, as well as secretion of IL-6, TNF (tumor necrosis factor), LT-β, IFNγ (interferon-γ) and TGF-β (transforming growth factor-β), and promote the recruitment of inflammatory cells. As such, IL-1, IL-6 and LT-β are well-known promoters of carcinogenesis; 14, 43, 49, 50 recent evidence suggests that recruited inflammatory cells, in particular 'ectopic lymphoid structures'which are often in close proximity to damaged tissue-promote the development of cancer. 51 Not only is there a strong correlation between DAMP expression and carcinogenesis in multiple tumors, but a plethora of DAMPs have been implicated in promoting inflammation and tumor development both in early stages of carcinogenesis as well as in established tumors ( Figure 1 ; Table 1 ). In addition to promoting tumor growth via increased inflammation, there is accumulating evidence that multiple DAMPs also exert immunosuppressive effects that ultimately promote the development or progression of tumors ( Figure 1 ; Table 1 ).
HMGB1
HMGB1 is overexpressed in precancerous states such as liver cirrhosis and gastric dysplasia, 52, 53 as well as in a wide range of tumors [54] [55] [56] [57] [58] and may trigger a number of inflammatory responses that promote tumor development and/or progression. HMGB1 triggers the recruitment of neutrophils, subsequent inflammation and amplification of injury in multiple injury models. 59, 60 Ablation of HMGB1 receptor RAGE suppresses carcinogenesis in multiple cancer models, including inflammation-induced liver and skin cancer, as well as a xenotransplant glioma model. [61] [62] [63] As such, HMGB1 promotes the recruitment and activation of intratumoral T cells in prostate cancer, which in turn recruit tumor-promoting macrophages. 64 Moreover, HMGB1 promotes the growth of hepatocellular carcinoma in concert with mitochondrial DNA via activation of TLR9. 31 TLR4, another receptor for HMGB1, is also expressed by tumor cells; activation of the TLR4 pathway has been associated with tumor cell survival, chemoresistance, and tumor progression and metastasis. 65 Of note, the HMGB1-TLR4/RAGE pathway has recently been involved in chemoresistance to docetaxel by inducing the secretory/cytoplasmic clusterin in prostate tumor cells, a potent anti-apoptotic protein that mediates BAX sequestration, preventing caspase 3 activation. 66 Chemotherapy-induced release of HMGB1 from necrotic colon cancer cells enhances the growth and metastasis of remnant cancer cells through RAGE 67 , whereas blockade of the HMGB1-RAGE axis inhibits tumor growth and metastasis 63 and enhances sensitivity to chemotherapy. 68 Moreover, HMGB1 released from hypoxic cells triggers endothelial cell proliferation in vitro and neoangiogenesis in vivo, 69 and expression levels of HMGB1 in tumors are associated with invasion and metastasis. 53 Interactions between HMGB1 and TIM-3, expressed on DCs, result in suppression of the therapeutic efficacy and of DNA vaccination and chemotherapy by decreasing the immunogenicity of nucleic acids released from dying tumor cells. 70 Hence, HMGB1 may not only promote carcinogenesis via the activation of inflammatory pathways, but also through immunosuppressive pathways.
ATP and adenosine
Although there are unusually high concentrations of extracellular ATP in the tumor interstitium as well as increased expression levels of the ATP receptor P2X7R on a variety of human cancers, 18, 71 there is only limited evidence in supporting their role in tumor promotion. Although P2X7 promotes inflammation, Figure 1 . DAMPs mediate tumor progression. Cellular release of DAMPs such as uric acid, HMGB1, S100 proteins, IL-1α and adenosine can promote tumor progression via distinct mechanisms and target cells. Adenosine and HMGB1 may contribute to immunosuppression; HMGB1 and IL-1α to angiogenesis; uric acid, HMGB1, S100 proteins and adenosine to tumor cell proliferation; and ATP, IL-1α, S100 proteins, HMGB1 and uric acid to inflammation.
largely mediated by activation of the inflammasome 72 and modulates myeloid-derived suppressor cell (MDSC) immunosuppressive functions, 73 the majority of studies show a protective role (see next section). The finding that P2X7R-deficiency exacerbated tumor development in a colitis-associated colon cancer model despite decreased inflammation 74 suggests only a limited role in P2X7R-mediated inflammation in promoting carcinogenesis. Adenosine is a potent anti-inflammatory DAMP that acts on a variety of cell types and contributes to limiting inflammatory response following injury. Increased adenosine levels in the tumor microenvironment contribute to tumor progression via suppression of T cells and natural killer cells. 19 Stimulation of A2A receptor decreases maturation and cytotoxic function of natural killer cells, leading to promotion of metastasis. 75 Moreover, regulatory T cells express ectonucleotidases CD39 and CD73 in a variety of tumors, 19, 76 resulting in increased generation of pericellular adenosine and A2A receptor-mediated inhibition of effector T cells. CD73 is also expressed on tumor cells or stroma, which further increases adenosine levels and contributes to immune evasion by suppressing T-cell recruitment and activation, as well as chemoresistance to doxorubicin in an A2A-dependent manner. [76] [77] [78] Accordingly, blockade of CD73 inhibits breast tumor growth and metastasis, 79 and increases doxorubicin-mediated anti-tumor immune response. 78 Moreover, a large number of studies have shown that adenosine triggers tumor proliferation via A1 and A3 receptors, 19 suggesting that this pathway may contribute to tumor progression. Furthermore, adenosine promotes chemotaxis and metastasis via A2B receptors. 79 S100 proteins Dysregulated expression of various members of the S100 protein family has been observed in many types of cancers, with tumor stage-and subtype-specific expression profiles. Similarly to HMGB1, S100A8/A9 and S100A12 circulating levels are upregulated in a number of chronic inflammatory diseases and types of tumors, and strongly correlate with disease course and/or severity. 34 In addition, the S100A8/A9-RAGE axis links inflammation and tumor promotion through activation of MAPK and NF-κB pathways. 61,80 S100 proteins have been ascribed with diverse DAMP functions following release from necrotic cells, mostly through interaction with RAGE, although interaction with TLR4 has been demonstrated in other settings. 60, 81 Interference with their expression or signaling pathways has subsequently revealed a complex role for the various S100 proteins in the growth and dissemination of established tumors, with effects both on cancer cell growth as well as on concomitant inflammation. 22 As such, the expression of S100A8 and S100A9 is induced by distant primary tumors, resulting in the attraction of myeloid cells in the premetastatic lung. 82 This is mediated by the induction of S100A8and S100A9-induced production of SAA3, which in turn activates TLR4 and facilitates metastasis. 83 In addition, S100A8 and S100A9 act directly on tumor cells, activating p38 MAPK, thereby promoting tumor cell migration. 82 Similarly, it has been shown that low concentrations of extracellular S100A8/9 also enhance NF-κB activation in tumor cells and promotes their growth through interactions with RAGE. 84 S100A4 expression is significantly increased in prostate cancer cell lines compared with normal prostate epithelial cells, and expression correlates with increased tumor grade. 85 A causative relationship between S100A4 expression and tumor progression has been demonstrated in colon cancer cells, where pharmacologic targeting of S100A4 via the anti-helmintic niclosamide profoundly inhibited growth and metastatic spread. 86 S100A4, however, apparently exhibits both tumor cell-intrinsic as well as extrinsic effects, as demonstrated by the ability of S100A4 from metastasesassociated stroma to bind to RAGE on tumor cells, leading to the secretion of paracrine factors and pro-inflammatory cytokines such as IL-8, CCL2, IL-6 and IL-1β, which in turn promote angiogenesis and pro-tumor immune responses. 87 Accordingly, both intracellular and extracellular S100A4 may represent promising therapeutic targets to prevent progression of neoplastic diseases.
In addition to promoting inflammation, recruitment of macrophages and tumor migration, S100 proteins also affect anti-tumor immune responses. As such, S100A9 enhances the production of MDSCs, thereby suppressing anti-tumor responses. S100A9deficient mice rejected implanted tumors, which was reversed by administration of wild-type MDSCs from tumor-bearing mice to S100A9-deficient mice. 88 Notably, RAGE-null mice exhibit reduced tumor growth in experimental skin and colon cancers, 61, 62, 89 and display reduced numbers of MDSC in tumor stroma, pointing at a central role for RAGE in the mediation of S100A8/A9-mediated MDSC recruitment. 90, 91 Uric acid Dying cells release their intracellular uric acid stores, and additional uric acid is generated post mortem during enzymatic degradation of nucleic acids. Extracellular uric acid triggers inflammatory responses to cell death, possibly through TLR4mediated NLRP3 inflammasome activation, 92 by mediating neutrophil activation, 93 as well as DC maturation and T-cell differentiation. 94 Moreover, cancer cells themselves respond to uric acid by increasing migratory activity. 95 Accordingly, elevated uric acid levels in patients have been associated with an excess cancer risk. 96 However, uric acid released from tumors subject to chemotherapy or immune rejection accelerates tumor regression. 97 
CONTRIBUTION OF DAMPS TO TUMOR INHIBITION/REJECTION VIA ICD AND OTHER MECHANISMS
Physiological cell death, such as apoptosis, has long been considered non-or low-inflammatory owing to the rapid removal of apoptotic cells by phagocytic cells, whereas pathological cell death, induced by physicochemical stress or noxious stimuli, such as necrosis, necroptosis and pyroptosis, has been described as inherently immunogenic and highly inflammatory. As cancer therapies often induce cell death via apoptosis and in addition can be immunosuppressive, either on their own or in combination with the commonly co-administered corticosteroids, the concept that tumor cell death triggered by cytostatic therapies might be immunogenic has long been ignored. 98 However, this traditional perspective of cell death has been challenged by the finding that in response to specific anti-cancer agents, tumor cells can undergo an ICD that combines modalities of apoptosis with the emission of DAMPs, fostering a potent, therapeutic reinforcing anti-tumor immune response (Figure 2) . Moreover, tumor cell death is not selectively apoptotic, as other death modalities including necrosis and necroptosis are also potently induced by cytostatic therapies, and necrosis is even commonly found in untreated tumors, often visible as necrotic tumor center. 17, 25, 26 Although the contribution of non-apoptotic forms of cell death including necrosis, necroptosis and pyroptosis to ICD is not as well-characterized, it is likely that non-apoptotic cell death commonly occurs in anti-cancer therapy strategies such as chemotherapy and irradiation. 17, 25, 26 There is accumulating evidence that DAMPs exert a key role in ICD. ICD strongly relies on the induction of an ER stress response triggered or accentuated by reactive oxygen species production. 6, 99 The combined action of ER stress and reactive oxygen species promotes the activation of DAMP signaling pathways, involving the pre-apoptotic exposure of the ER chaperone CRT on the cell surface (ecto-CRT), 5 early apoptotic secretion of ATP 100 and post-apoptotic release of HMGB1. 101 Engagement of these DAMPs with various target DAMPs and cancer C Hernandez et al receptors present on immune cells, leads to the elicitation of a potent anti-tumor immunity ( Figure 2 ; Table 1 ). Several studies demonstrated that interfering with the emission of these DAMPs compromised the anti-tumor immune response, 5,23,100 providing evidence for its critical role in shaping cancer cell immunogenicity. However, a recent study using spontaneous mammary tumor models demonstrated that the adaptive immune system is dispensable for the therapeutic efficacy of oxaliplatin, doxorubicin and cisplatin, 102 raising concerns about experimental models used for ICD studies. In fact, most landmark studies on ICD rely on functional data from cell line-based models. 5, 6, 70, 100, [103] [104] [105] Transplanted cell lines are likely to differ substantially in their genetic profile to endogenously arising tumors and thus may induce immune responses that cannot be triggered by endogenously arising tumors. In addition to more profoundly altered genetic profiles, endogenous tumors undergo constant immunoediting, 106 whereas transplanted cell lines lack this selection and are most likely much more immunogenic owing to a higher load of tumor antigens to which the host immune system can respond. Some of the concerns are alleviated by the inclusion of human data in recent studies, showing poorer survival in patients with a loss-of-function of FPR1 105 or more rapid development of metastasis in patients with a loss-of-function of P2X7R. 103 Additional studies in models with endogenously arising tumors would further confirm the relevance of ICD as well as the contribution of DAMPs to this process.
Calreticulin
CRT is one of the best-characterized mediators of ICD. CRT translocation triggered by chemotherapy and UVC irradiation relies on PERK-mediated eIF2α phosphorylation followed by capase-8-mediated BAP31-dependent activation of BAX/BAK proteins. 99 However, eIF2α phosphorylation and caspase-8 are dispensable for photodynamic therapy-induced ecto-CRT exposure. 6 Ecto-CRT functions as a pro-phagocytic signal for DCs 5 and promotes the IL-6-and TNF-mediated priming of T-helper 17 (Th17) cells through scavenger receptor CD91. 107 The presence of ecto-CRT has also been demonstrated in immune cells, including DCs, where it was found to interact with NY-ESO-1, a tumor-associated antigen with distinctively strong immunogenicity, 108 confirming its role in linking tumor and host immune response. Of note, the recombinant N-terminal fragment of CRT was sufficient to stimulate B cells and macrophage activation, 109 arguing for a potent immunostimulatory role of the soluble form of CRT. Interestingly, resistance to anti-cancer vaccination induced by ICD was associated with a defect in ecto-CRT exposure resulting from low endogenous CRT protein levels and could be rescued by exogenous reconstitution of ecto-CRT. 110 In the same study, CRT expression was a predictive biomarker of anti-cancer therapy response in cancer patients and a potential regulator of phagocytosis in tumors in ICD clinical settings. 110 Although necessary, CRT translocation is not sufficient to elicit an anti-tumor response, which relies on additional signaling pathways involved in antigen processing and presentation and immune cell polarization.
ATP and adenosine
Extracellular ATP is a critical effector in ICD. 103 Similarly to CRT translocation, ATP release seems to be dependent on cell death stimulus and modalities. Photodynamic therapy-induced, preapoptotic release of ATP relies on the overlapping classical secretory pathway as well as PERK-regulated secretory and PI3 kinase-dependent extracellular trafficking pathways and is independent of BAX/BAK. Early apoptotic secretion of ATP has been shown to be pannexin 1 hemichannels-dependent following UVC irradiation, 111 and autophagy-dependent in dying cells undergoing chemotherapy (anthracyclines and oxaliplatin). 6, 100 Once released from dying cancer cells, ATP displays a dual effect, both acting as a chemotaxis inducer and activator of the inflammasome pathway depending on its extracellular concentration. 112 ATP released by apoptotic cells has been shown to promote P2Y2R dependent-phagocytic clearance 113 and P2X7R-dependent activation of the NLRP3 inflammasome by chemotherapeutic agents. The subsequent activation of caspase-1 then leads to the secretion of IL-1β and polarization of IFNγ-producing CD8 + T cells. 100, 103 ATP from dying cancer cells attracts myeloid cells to the site of cell death, 104 and ATP receptors P2Y2R and P2X7R stimulate the recruitment of DCs and inflammatory cells into the tumor stroma as well as the maturation of T cells into the cytotoxic CD8 + phenotype. 103, 104, 114 P2X7R, which has a low affinity for ATP, is critical to support anti-tumor immune response and restricts tumor progression specifically via its expression on host hematopoietic cells. 114 Ivermectin, an anti-parasitic drug, has been shown to display anti-tumor properties in vivo, owing to its ability to stimulate P2X4R/P2X7R/Pannexin 1 signaling and to promote a novel form of cancer cell death involving a combination of apoptosis and highly inflammatory regulated necrosis, consistent with pyroptosis. 115 Noteworthy, adenosine, resulting from ATP hydrolysis by the ectoenzymes CD73 and CD39, exerts effects that are often opposite to those of ATP (see details in previous section), such as the promotion of an immunosuppressive environment via A2A receptors 76, 116, 117 as well as chemotaxis and metastasis via A2B receptors. 79 However, adenosine can also induce tumor cell death, via A1, A2A, A2B and A3 receptors, 19, 118 thereby additionally contributing to limit tumor growth ( Figure 2 ). Therefore, the kinetics of ATP release and conversion to adenosine, as well as the large number of receptors for ATP and adenosine need to be taken into consideration when targeting this system for ICD induction.
Annexin A1/FPR1 FPR1 is a PRR that-besides recognizing N-formylated peptides from bacteria-also interacts with several DAMPs including annexin A1. Recent studies have shown that a single-nucleotide polymorphism, which suppresses FPR1 signaling, was associated with reduced survival in patients receiving adjuvant chemotherapy for breast or colorectal cancer. 105 In experimental models, FPR1 expression on the host and expression of FPR1 ligand annexin A1 on tumor cells were required for chemotherapyinduced reduction of tumor growth. Likewise, treatment with FPR1 antagonist cyclosporine H also abolished anti-cancer effects of chemotherapy. 105 Mechanistically, FPR1 was dispensable for the recruitment of DCs to the tumor bed, but was required for DCs to come into close proximity to dying cancer cells, to take up tumor-associated antigens and cross-present them to T cells. 105 
HMGB1
Although it was initially thought that HMGB1 release primarily occurred following necrosis, several studies pointed out that HMGB1 release could also be associated with apoptosis, specifically during secondary necrosis. Post-apoptotic release of HMGB1, as triggered by radiotherapy or chemotherapy (anthracyclines), enhances DC-mediated antigen presentation via TLR4. 23 In this context, HMGB1 acts as a critical mediator of the TLR4-dependent processing of exogenous tumor antigens by DCs, but does not promote DC migration and maturation, which primarily involves the HMGB1-RAGE axis. 119 HMGB1 stimulates DC maturation through RAGE and leads to T-helper 1 polarization. 120 Interestingly, RAGE-mediated HMGB1 endocytosis has recently been described as a trigger of pyroptosis in macrophages, 121 which could represent a potential feedback mechanism promoting anti-tumor immunity during ICD. Although chemotherapyinduced HMGB1-TLR4 axis signaling has mainly been involved in eliciting anti-tumor responses, HMGB1 has also been shown to foster an immunosuppressive and pro-tumor environment (see previous section; Figure 1 , Table 1 ), which could negatively impact the outcome of anti-cancer therapies. The opposite roles of HMGB1 in tumorigenesis and ICD following anti-cancer therapies might be attributable to its redox status that defines its molecular interaction and activities, 122, 123 and has a key role in cell fate regulation. 124, 125 Indeed, reducible HMGB1 induces RAGE/Beclin1dependent autophagy in cancer cells, promoting tumor resistance to chemotherapeutic agents or radiotherapy, whereas oxidized HMGB1 enhances the cytotoxicity of these chemotherapeutics and triggers apoptosis mediated by the caspase-9/-3 intrinsic pathway. 124 Of note, the extracellular milieu, known to be oxidated under physiologic conditions, is altered and highly variable under pathologic conditions, such as cancer, as evidenced by in vitro culture of different cancer cell lines. 126 In vivo, the tumor microenvironment tends to be pro-oxidative, which would diminish the pro-inflammatory properties of HMGB1 via oxidation-mediated inactivation. 122, 123, 127 Finally, loss of membrane integrity occurring during primary or secondary necrosis leads to the release of uric acid, DNA, ATP and N-formyl peptides that can participate and reinforce the anti-tumor response. As such, DNA released after chemotherapyinduced cell death 70 can efficiently stimulate an antigen-specific anti-tumor immune response, and uric acid enhances tumor immune rejection. 97 
TUMOR-SPECIFIC DAMPS VERSUS DAMPS FROM NON-TUMOR CELLS FOLLOWING CYTOSTATIC THERAPY
The most profound release of DAMPs occurs in response to cytostatic therapies. However, these therapies are by no means tumor-specific and induce cell death in rapidly proliferating cells in many organs including bone marrow, gastrointestinal tract and hair follicles. Hence, it is likely that a significant proportion of DAMPs are released from non-tumor compartments in response to cytostatic therapies. Additional studies are required to determine whether DAMPs from healthy cells in these compartments modulate inflammatory and immune responses including ICD in the setting of cytostatic therapies.
Another key point that has not been sufficiently addressed is the potential role of yet unknown tumor cell-specific DAMPs. The majority of studies on the role of DAMPs in tumors have been based on DAMPs discovered in models of non-malignant disease. Because of the profound aberrations of a wide range of pathways DAMPs and cancer C Hernandez et al in tumor cells, tumor-specific DAMPs could be generated by a number of mechanisms, including post-translational alterations and alterations in the secretion of mediators that are typically retained within healthy cells. In this regard, tumor-specific DAMPs could also be a cargo of exosomes, whose secretion is commonly upregulated in tumor cells.
EXPLOITING DAMPS FOR TUMOR PREVENTION OR ANTI-TUMOR THERAPY
It is conceivable that DAMPs can be targeted in different stages of carcinogenesis. Considering that constant cell death favors tumor development in organs such as the liver, one could envision blocking DAMP signaling as tumor-preventative strategy. On the other hand, the recently established key role of DAMPs in the immune system's response to tumors, in particular in the setting of anti-tumor therapies, suggests that activating DAMPs signaling pathways might be exploited for anti-tumor therapies, analogous to PRR-mediated activation of anti-tumor pathways by 'Coley's toxin'. However, this view is likely to be simplistic as PRR-induced immunostimulatory signals may not only fail in chronic settings but even get 'hijacked' by the tumor, resulting in tumor-promoting inflammation rather than an efficient anti-tumor response in the long run. For this reason, it appears more promising to activate DAMP signaling pathways in conjunction with cystostatic therapies, as well as therapies that prevent immune exhaustion such as checkpoint inhibitors. This might ensure continuous activation of anti-tumor responses and ICD, and might be particular appealing in settings when tumor mass is small and release of DAMPs minimal, for example, as a type of adjuvant therapy after curative resection. In this regard, a recent study has identified FPR1 as a determinant of chemotherapy-induced immunity and survival in adjuvant settings. Although these data are promising and may open new possibilities for treatment, we still need a better understanding of the role of specific DAMPs and their cellular targets as these responses are likely to be mediated by multiple DAMPs in complex signaling networks. It is likely that contribution of DAMPs and their receptors to carcinogenesis and ICD are organ-, tumor-and context-specific, and that key DAMPs in this setting are yet-to-be identified molecules or DAMPs with specific post-translational modifications. Moreover, it is conceivable that immunosuppressive effects of chemotherapy may dominate in some organs as suggested by studies that demonstrated chemotherapyinduced plasma cell recruitment and subsequent plasma cellmediated inhibition of chemotherapeutic efficacy. 128 Finally, it is also likely that DAMPs shape the tumor microenvironment which in turn provides essential support for the tumor. 129 Hence, targeting select DAMPs that contribute to a tumorpromoting microenvironment may be beneficial. In summary, further understanding of the diverse roles of DAMPs in cancer is required before DAMPs can be exploited for therapeutic strategies, and it is likely that these therapeutic approaches might incorporate both activation and inhibition of DAMP signaling pathways.
